Aina Karen Anthi

Aina Karen Anthi

Auto-generated profile, based on publicly available information

Aina Karen Anthi

Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFStian Foss
Stian Foss
SSSiri Aastedatter Sakya
Siri Aastedatter Sakya
LALeire Aguinagalde
Leire Aguinagalde
MLMarta Lustig
Marta Lustig
JSJutamas Shaughnessy
Jutamas Shaughnessy
JAJan Terje Andersen
Jan Terje Andersen
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby potentially patient compliance. Here, we report on an Fc-engineered variant with three amino acid substitutions Q311R/M428E/N434W (REW), that enhances plasma half-life and mucosal distribution, as well as allows for needle-free delivery across respiratory epithelial barriers in human FcRn transgenic mice. In addition, the Fc-engineered variant improves on-target complement-mediated killing of cancer cells as well as both gram-positive and gram-negative bacteria. Hence, this versatile Fc technology should be broadly applicable in antibody design aiming for long-acting prophylactic or therapeutic interventions.

30 December 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
TTTrung The Tran
Trung The Tran
EVEline Benno Vaage
Eline Benno Vaage
AMAdi Mehta
Adi Mehta
ACAdity Chopra
Adity Chopra
LTLisa Tietze
Lisa Tietze
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.

1 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
EVEline Benno Vaage
Eline Benno Vaage
MBMalin Bern
Malin Bern
SBSopisa Benjakul
Sopisa Benjakul
JAJan Terje Andersen
Jan Terje Andersen
Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.

22 December 2020 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
KAKristin Hovden Aaen
Kristin Hovden Aaen
AAAina Karen Anthi
Aina Karen Anthi
ISInger Sandlie
Inger Sandlie
JNJeannette Nilsen
Jeannette Nilsen
SMSimone Mester
Simone Mester
JAJan Terje Andersen
Jan Terje Andersen
The neonatal Fc receptor (FcRn) was first recognized for its role in transfer of maternal IgG to the foetus or newborn, providing passive immunity early in life. However, it has become clear that the receptor is versatile, widely expressed and plays an indispensable role in both immunological and non‐immunological processes throughout life. The receptor rescues immunoglobulin G (IgG) and albumin from intracellular degradation and shuttles the ligands across polarized cell barriers, in all cases via a pH‐dependent binding‐and‐release mechanism. These processes secure distribution and high levels of both IgG and albumin throughout the body. At mucosal sites, FcRn transports IgG across polarized epithelial cells where it retrieves IgG in complex with luminal antigens that is delivered to tissue‐localized immune cells. In dendritic cells (DCs), FcRn orchestrates processing of IgG‐opsonized immune complexes (ICs) in concert with classical Fcγ receptors, which results in antigen presentation and cross‐presentation of antigenic peptides on MHC class II and I to CD4+ and CD8+ T cells, respectively. Hence, FcRn regulates transport of the ligands within and across different types of cells, but also processing of IgG‐ICs by immune cells. As such, the receptor is involved in immune surveillance and protection against infections. In this brief review, we highlight how FcRn expressed by hematopoietic and non‐hematopoietic cells contributes to immune regulation at mucosal barriers—biology that can be utilized in development of biologics and subunit vaccines for non‐invasive delivery.

28 November 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
SBSopisa Benjakul
Sopisa Benjakul
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
MVMarina Vaysburd
Marina Vaysburd
HLHeidrun Elisabeth Lode
Heidrun Elisabeth Lode
JAJan Terje Andersen
Jan Terje Andersen
Immunocompromised patients often fail to raise protective vaccine-induced immunity against the global emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Although monoclonal antibodies have been authorized for clinical use, most have lost their ability to potently neutralize the evolving Omicron subvariants. Thus, there is an urgent need for treatment strategies that can provide protection against these and emerging SARS-CoV-2 variants to prevent the development of severe coronavirus disease 2019. Here, we report on the design and characterization of a long-acting viral entry-blocking angiotensin-converting enzyme 2 (ACE2) dimeric fusion molecule. Specifically, a soluble truncated human dimeric ACE2 variant, engineered for improved binding to the receptor-binding domain of SARS-CoV-2, was fused with human albumin tailored for favorable engagement of the neonatal fragment crystallizable receptor (FcRn), which resulted in enhanced plasma half-life and allowed for needle-free transmucosal delivery upon nasal administration in human FcRn-expressing transgenic mice. Importantly, the dimeric ACE2-fused albumin demonstrated potent neutralization of SARS-CoV-2 immune escape variants.

11 April 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DPDiego Pilati
Diego Pilati
EAEugene Kusi Agyei
Eugene Kusi Agyei
MEMarwa Elkhashab
Marwa Elkhashab
EFElisabeth Fuchs
Elisabeth Fuchs
INIan Helstrup Nielsen
Ian Helstrup Nielsen
KHKen Howard
Ken Howard
CpG-oligodeoxynucleotide (CpG ODN)-based toll-like receptor (TLR) agonists are promising immunostimulatory adjuvants, however, low entry into TLR-rich cellular endosomal compartments and poor lymphatic accumulation limit clinical translation. In this work, we introduce a recombinant human serum albumin (rHA)-CpG ODN covalent conjugate (rHA-CpG) designed to exploit the neonatal Fc receptor (FcRn)-driven albumin cellular sorting pathway to maximise CpG delivery into TLR9-rich endosomes and accumulate in lymph nodes. Site-selective conjugation of CpG to albumin cysteine 34, distant from its main FcRn binding interface, resulted in a retained pH dependent human FcRn binding, and receptor-driven endosomal trafficking in a cellular recycling assay. Induction of tumour necrosis factor (TNF) secretion in THP-1 cells and interferon alpha (IFN-α) in human hematopoietic stem and progenitor cell (HSPC)-derived plasmacytoid dendritic cells (pDCs), in contrast, to a myeloid differentiation primary response 88 (MyD88) and TLR9 knockout cells, respectively, support TLR9-engagement. The rHA-CpG construct induced greater TNF-α than free CpG ODN in mouse RAW 264.7 cells, and in human peripheral blood mononuclear cells (PBMCs) and expansion of classical (CD14+CD16-) monocytes. Furthermore, greater accumulation of Cy5.5-labelled CpG in the inguinal (>3-fold) and axillary (>18-fold) lymph nodes was observed when conjugated to rHA compared to an unconjugated rHA/CpG mix following subcutaneous injection in mice. Moreover, increased LN accumulation of an rHA variant engineered with high FcRn-binding affinity supports an FcRn-driven mechanism. Demonstration of FcRn-mediated albumin targeting at intra- and extracellular sites provides the mechanistic basis for potent immune induction observed using the novel rHA-CpG conjugate design class introduced in this work.